B. mallei and B. pseudomallei (""""""""B. (pseudo)mallei""""""""), two closely related Gram-negative bacteria, are serious potential bioterrorist agents listed on CDC/MMWR's category B list. These organisms cause life-threatening infections (Glanders' disease and Melioidosis, respectively), where antibiotic treatment is sometimes insufficient. The virulence factors of the two species are not well understood, and it is difficult to distinguish these species from each other and also from the closely related avirulent species B. thailandensis. B.(pseudo)mallei is also a civilian problem causing septicemia in Southeast Asia. Another Burkholderia species, B. cepacia, is a more common civilian problem that increases mortality and morbidity of cystic fibrosis patients. To better treat and diagnose B.(pseudo)mallei, we will develop monoclonal antibodies (mAbs) against potential virulence factors: components of the type III secretion system (TTSS). The presence of TTSS has been correlated to virulence of Burkholderia. Also, since several other invasive Gram-negative bacteria utilize TTSS to enter host cells, it is plausible that TTSS are critical for Burkholderia's virulence as well. TTSS components will be cloned and expressed in E.coli to generate sufficient quantities of purified antigen to generate mAbs. Fully human mAbs will be generated by phage display technology. Initial screening of the mAbs for reactivity will be conducted against a panel of Burkholderia isolates cultivated under different conditions, mAbs of interest will be further evaluated for protective capability in both in vitro and subsequently in vivo small animal models. We will also investigate potential differences of TTSS genes among isolates of Burkholderia. In summary the primary objectives of the project are: -Development of mAbs with utility in diagnosing and treating B.(pseudo)mallei and other Burkholderia species, including B.cepacia. -Improved understanding of the pathogenicity of B.(pseudo)mallei as a basis for potential vaccine development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI056383-02
Application #
6799209
Study Section
Special Emphasis Panel (ZAI1-ALR-M (M3))
Program Officer
Schaefer, Michael R
Project Start
2003-09-15
Project End
2006-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
2
Fiscal Year
2004
Total Cost
$415,395
Indirect Cost
Name
Cangene Corporation
Department
Type
DUNS #
City
Mississauga
State
ON
Country
Canada
Zip Code
Druar, Chris; Yu, Fei; Barnes, Jodie L et al. (2008) Evaluating Burkholderia pseudomallei Bip proteins as vaccines and Bip antibodies as detection agents. FEMS Immunol Med Microbiol 52:78-87
Soltes, Glenn; Hust, Michael; Ng, Kitty K Y et al. (2007) On the influence of vector design on antibody phage display. J Biotechnol 127:626-37